Fine bronchitis is currently a chronic, pan-bronchial inflammatory reaction with an insufficiently defined cause, and treatment is currently mainly symptomatic. The preferred clinical treatment is erythromycin therapy, using treatment aimed not at its anti-inflammatory effect, but at the effects associated with the anti-inflammatory effect and the potential immunomodulatory effect, enhancing the immune cells’ role in phagocytosis of pathogens and improving immunity. Another symptomatic treatment is the presence of wheezing and shortness of breath, which can be treated with appropriate glucocorticoids, such as dexamethasone, methylprednisone, prednisone, budesonide, etc. In addition, oxygen therapy and mechanical ventilation can be chosen for the presence of respiratory failure. For the combination of other pathogenic infections, such as bacteria, piperacillin, levofloxacin, tobramycin, ceftazidime and other drugs can be chosen for treatment.